Consensus summary of aerosolized antimicrobial agents: Application of guideline criteria insights from the society of infectious diseases pharmacists

Pharmacotherapy

Volumn 30, Issue 6, 2010, Pages 562-584

  Le, Jennifer ^a,b   Ashley, Elizabeth Dodds ^c   Neuhauser, Melinda M ^d   Brown, Jack ^c,e   Gentry, Chris ^f   Klepser, Michael E ^g   Marr, Ann Marie ^h   Schiller, Daryl ⁱ   Schwiesow, Joshua N ^j   Tice, Sally ^k   VandenBussche, Heather L ^g   Wood, G Christopher ^l  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g FERRIS STATE UNIVERSITY   (United States)

^h HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ SAINT BARNABAS MEDICAL CENTER   (United States)

^j Kaiser Foundation Health Plan   (United States)

^k GEISINGER MEDICAL CENTER   (United States)

^l UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

Aerosolized antibiotic; Aerosolized tobramycin; Aminoglycosides; Antifungal; Drug safety; Evidence based medicine; Infectious diseases; Nebulized antibiotics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZTREONAM; AZTREONAM LYSINE; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; GENTAMICIN; ITRACONAZOLE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; SALBUTAMOL; SISOMICIN; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ZANAMIVIR;

AEROSOL; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; AUDITORY OTOTOXICITY; BRONCHIECTASIS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONJUNCTIVITIS; CONSENSUS DEVELOPMENT; COUGHING; CYSTIC FIBROSIS; DECREASED APPETITE; DISEASE EXACERBATION; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; GLUCOSE INTOLERANCE; HEARING LOSS; HEMATOLOGIC MALIGNANCY; HOARSENESS; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; INFLUENZA; INVASIVE ASPERGILLOSIS; JET NEBULIZER; KIDNEY DYSFUNCTION; LUNG DISEASE; LUNG INFECTION; LUNG TOXICITY; LUNG TRANSPLANTATION; METERED DOSE INHALER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOBACTERIOSIS; MYCOSIS; NAUSEA AND VOMITING; NEBULIZER; NEPHROTOXICITY; NON CYSTIC FIBROSIS BRONCHIECTASIS; NOSE CONGESTION; PATHOGENESIS; PHYSICIAN; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRACTICE GUIDELINE; PROSPECTIVE PAYMENT; PSEUDOMONAS INFECTION; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; TASTE DISORDER; THORAX PAIN; THROAT IRRITATION; TINNITUS; TREATMENT DURATION; ULTRASONIC NEBULIZER; VESTIBULAR OTOTOXICITY; WHEEZING;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFECTIVE AGENTS; CONSENSUS; DRUGS, INVESTIGATIONAL; HUMANS; NEBULIZERS AND VAPORIZERS; PATIENT EDUCATION AS TOPIC; RESPIRATORY TRACT INFECTIONS;

EID: 77952911090     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.6.562     Document Type: Review

References (189)

1. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873 (Pubitemid 38344143)
2. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-177 (Pubitemid 46084814)
3. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-237
4. Eisenberg J, Pepe M, Williams-Warren J, et al, for the Aerosolized Tobramycin Study Group. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111:955-962 (Pubitemid 27171467)
5. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-765 (Pubitemid 16247735)
6. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93:3654-3661
7. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-1407
8. Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy 2002;22(3 pt 2):S71-9.
9. Wood GC, Swanson JM. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 2007;67:903-914 (Pubitemid 46607390)
10. Boe J, Dennis JH, O'Driscoll BR, et al. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001;18:228-242 (Pubitemid 32717452)
11. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines - American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335-371
12. Wood GC, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000;20:166-181 (Pubitemid 30073837)
13. Dalton-Bunnow MF. Review of sulfite sensitivity. Am J Hosp Pharm 1985;42:2220-2226
14. Kuhn RJ. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 2002;22(3 pt 2):S80-5.
15. Moore RH. Use of medication nebulizers in children. In: Basow DS, ed. Waltham, MA: UpToDate, Inc., 2009. Available from www.uptodate.com.
16. Asmus MJ, Milavetz G, Tice AL, Teresi ME. In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers. Pharmacotherapy 2001;21:534-539
17. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 2007;52:866-884
18. Bayat M, Cook AM. Intrapulmonary administration of medications. J Neurosci Nurs 2004;36:231-235
19. Newman SP, Pellow PG, Clarke SW. In vitro comparison of DeVilbiss jet and ultrasonic nebulizers. Chest 1987;92:991-994
20. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110:498-505. (Pubitemid 26269284)
21. Campbell PW III, Saiman L. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 1999;116:775-788 (Pubitemid 29428499)
22. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998;26:31-39 (Pubitemid 28028437)
23. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-226 (Pubitemid 34754166)
24. American Pharmaceutical Partners, Inc. NebuPent (pentamidine for inhalation) product information. Schaumburg, IL; 2002.
25. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care 2009;54:754-768
26. Chastre J. NKTR-061 achieves safe serum concentrations after repeat dosing in intubated, mechanically ventilated patients with gram-negative pneumonia: a pharmacokinetic study (poster 720). In: Program and abstracts of the international conference of the American Thoracic Society. New York, NY: American Thoracic Society, 2007.
27. Luyt CE. NKTR-061 (inhaled amikacin) achieves high epithelial lining fluid concentrations in gram-negative pneumonia in intubated and mechanically ventilated patients: a pharmacokinetic study (poster 710). In: Program and abstracts of the international conference of the American Thoracic Society. New York, NY: American Thoracic Society, 2007.
28. Niederman MS. NKTR-061 (inhaled amikacin) reduces intravenous antibiotic use in intubated mechanically ventilated patients during treatment of gram-negative pneumonia (poster 718). In: Program and abstracts of the international conference of the American Thoracic Society. New York, NY: American Thoracic Society, 2007.
29. Niederman MS. NKTR-061 (inhaled amikacin) achieves high tracheal aspirate concentrations in intubated, mechanically ventilated patients with gram-negative pneumonia: a pharmacokinetic study (poster 719). In: Program and abstracts of the international conference of the American Thoracic Society. New York, NY: American Thoracic Society, 2007.
30. Nektar Therapeutics. Research and development pipeline. Available from http://www.nektar.com/product-pipeline/all-phases.html. Accessed April 10, 2009.
31. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
32. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003;75: 1571-1574 (Pubitemid 36597298)
33. Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006;6:2765-2773 (Pubitemid 44571699)
34. Cystic Fibrosis Foundation. Patient registry 2007 annual report. Available from http://wwwcfforg/UploadedFiles/research/ClinicalResearch/2007- Patient-Registry-Reportpdf. Accessed April 12, 2009.
35. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
36. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-287
37. Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 2005;26:305-308
38. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767
39. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-969
40. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2003;(3):CD001021.
41. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849
42. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25: 88-92.
43. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-726
44. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005;26:458-461
45. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335
46. Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38:314-320
47. Ramsey BW, Pepe MS, Quan JM, et al, for the Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
48. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-48
49. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746 (Pubitemid 23170123)
50. Carswell F, Ward C, Cook DA, Speller DC. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. Br J Dis Chest 1987;81:356-360 (Pubitemid 17164863)
51. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-664
52. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33:305-311
53. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-838
54. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928
55. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009;135:1223-1232
56. Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111:599-605. (Pubitemid 17140544)
57. Stephens D, Garey N, Isles A, Levison H, Gold R. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983;2:209-211 (Pubitemid 13040524)
58. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 pt 1):481-485
59. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44.
60. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127:1420-1426 (Pubitemid 46224309)
61. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-480 (Pubitemid 29364062)
62. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155:2024-2029
63. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007;37:495-498 (Pubitemid 46855088)
64. Stockley RA, Hill SL, Burnett D. Nebulized amoxicillin in chronic purulent bronchiectasis. Clin Ther 1985;7:593-599 (Pubitemid 15238797)
65. Hill SL, Morrison HM, Burnett D, Stockley RA. Short-term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986;41:559-565 (Pubitemid 16070391)
66. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130:1503-1510
67. el-Din MA, Palmer LB, el-Tayeb MN, Khalil I, Gabr MS. Nebulizer therapy with antibiotics in chronic suppurative lung disease. J Aerosol Med 1994;7:345-350
68. Klastersky J, Huysmans E, Weerts D, Hensgens C, Daneau D. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest 1974;65: 650-654
69. Klastersky J, Hensgens C, Noterman J, Mouawad E, Meunier-Carpentier F. Endotracheal antibiotics for the prevention of tracheobronchial infections in tracheotomized unconscious patients: a comparative study of gentamicin and aminosidin-polymyxin B combination. Chest 1975;68:302-306
70. Levine BA, Petroff PA, Slade CL, Pruitt BA Jr. Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. J Trauma 1978;18:188-193
71. Vogel F, Werner H, Exner M, Marx M. Prophylaxis and treatment of respiratory tract infection in ventilated patients by endotracheal administration of aminoglycosides [in German]. Dtsch Med Wochenschr 1981;106:898-903.
72. Greenfield S, Teres D, Bushnell LS, Hedley-Whyte J, Feingold DS. Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on the colonization pattern of the upper respiratory tract of seriously ill patients. J Clin Invest 1973;52:2935-2940
73. Klick JM, du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest 1975;55:514-519
74. Feeley TW, du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, Feingold DS. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975;293:471-475
75. Lode H, Hoffken G, Kemmerich B, Schaberg T. Systemic and endotracheal antibiotic prophylaxis of nosocomial pneumonia in ICU. Intensive Care Med 1992;18(suppl 1):S24-7.
76. Rathgeber J, Zielmann S, Panzer C, Burchardi H. Prevention of pneumonia by endotracheal micronebulization of tobramycin [in German]. Anasthesiol Intensivmed Notfallmed Schmerzther 1993;28:23-29
77. Rouby JJ, Poete P, Martin de Lassale E, et al. Prevention of gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients: histologic and bacteriologic study. Intensive Care Med 1994;20:187-192 (Pubitemid 24088581)
78. Wood GC, Boucher BA, Croce MA, Hanes SD, Herring VL, Fabian TC. Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 2002;22:972-982
79. Claridge JA, Edwards NM, Swanson J, et al. Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Surg Infect (Larchmt) 2007;8:83-90.
80. Pines A, Raafat H, Siddiqui GM, Greenfield JS. Treatment of severe Pseudomonas infections of the bronchi. Br Med J 1970;1:663-665
81. Klastersky J, Geuning C, Mouawad E, Daneau D. Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 1972;61:117-120
82. Klastersky J, Carpentier-Meunier F, Kahan-Coppens L, Thys JP. Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest 1979;75:586-591 (Pubitemid 9178586)
83. Mohr AM, Sifri ZC, Horng HS, et al. Use of aerosolized aminoglycosides in the treatment of gram-negative ventilator-associated pneumonia. Surg Infect (Larchmt) 2007;8:349-357
84. Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009;29:1054-1060
85. Pines A, Raafat H, Plucinski K. Gentamicin and colistin in chronic purulent bronchial infections. Br Med J 1967;2:543-545
86. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-757
87. Berlana D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62:39-47. (Pubitemid 40394633)
88. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006;53:274-278
89. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007;58:235-240
90. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. Respir Med 2008;102:407-412 (Pubitemid 351179979)
91. Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF, Langrehr D. Nosocomial gram-negative pneumonia in critically ill patients: a 3-year experience with a novel therapeutic regimen. Intensive Care Med 1986;12:419-423
92. Myers SE, Devine SM, Topper RL, et al. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992;8:229-233
93. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997;16:364-368 (Pubitemid 27271824)
94. Behre GF, Schwartz S, Lenz K, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995;71:287-291 (Pubitemid 26002066)
95. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-1408 (Pubitemid 351589940)
96. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001;20:1274-1281
97. Borro JM, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008;40:3090-3093
98. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series [online exclusive article]. BMC Pulm Med 2007;7:2. Available from http://www.biomedcentral.com/1471-2466/7/2.
99. Bozzette SA, Finkelstein DM, Spector SA, et al, for the NIAID AIDS Clinical Trials Group. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-699
100. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al, for the Dutch AIDS Treatment Group. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-1841
101. Girard PM, Landman R, Gaudebout C, et al, for the PRIO Study Group. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993;328:1514-1520
102. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995;20:531-541
103. Hardy WD, Feinberg J, Finkelstein DM, et al, for the AIDS Clinical Trials Group Protocol 021. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;327:1842-1848
104. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992;6:1169-1174
105. Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999;180:369-376
106. Hallal A, Cohn SM, Namias N, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 2007;8:73-82.
107. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162:328-330
108. Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J Chemother 2005;17:536-538
109. McCall CY, Spruill WJ, Wade WE. The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis. Ther Drug Monit 1989;11:692-695
110. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
111. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-569 (Pubitemid 39177490)
112. Sorensen VJ, Horst HM, Obeid FN, Bivins BA. Endotracheal aminoglycosides in gram-negative pneumonia: a preliminary report. Am Surg 1986;52:391-394 (Pubitemid 16097275)
113. Stillwell PC, Kearns GL, Jacobs RF. Endotracheal tobramycin in gram-negative pneumonitis. Drug Intell Clin Pharm 1988;22:577-581
114. Day AJ, Williams J, Mckeown C, et al. Evaluation of inhaled colomycin in children with cystic fibrosis (poster R9c03). In: Proceedings of the 10th international cystic fibrosis congress, Sydney, Australia. Excerpta Medica Asia Pacific Congress Series 1988;74:206.
115. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis [letter]. Lancet 1985;1:865.
116. Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43:47-58.
117. Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J 1984;20:43-45 (Pubitemid 14123235)
118. Nathanson I, Cropp G, Li P, Neter P. Effectiveness of aerosolized gentamicin in cystic fibrosis (CF) [abstract]. Cystic Fibrosis Club Abstracts 1985;26:145.
119. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987;81:272-279
120. Maiz L, Canton R, Mir N, Baquero F, Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 1998;26:287-289
121. Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001;120(3 suppl):S114-17.
122. Crowther Labiris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis: a pilot study. Am J Respir Crit Care Med 1999;160(5 pt 1):1711-1716
123. Twiss J, Byrnes C, Johnson R, Holland D. Nebulised gentamicin - suitable for childhood bronchiectasis. Int J Pharm 2005;295:113-119 (Pubitemid 40558794)
124. Kleinschmidt R, Rommelsheim K, Exner M, Vogel F. The effectiveness of intratracheal antibiotic administration: clinical, microbiologic and pharmacologic results [in German]. Anasth Intensivther Notfallmed 1989;24:143-146
125. Brown RB, Phillips D, Barker MJ, Pieczarka R, Sands M, Teres D. Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B. Am J Infect Control 1989;17:121-125
126. Michalopoulos A, Kasiakou SK, Falagas ME. The significance of different formulations of aerosolized colistin. Crit Care 2005;9:417-418
127. Mohammad RA, Klein KC. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother 2006;40:2148-2154
128. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG. Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006;50:1852-1854
129. Beyer J, Schwartz S, Barzen G, et al. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994;22:143-148
130. Diot P, Rivoire B, Le Pape A, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995;8:1263-1268
131. Monforte V, Ussetti P, Lopez R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009;28:170-175
132. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006;6:3008-3016
133. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis 1993;147:1271-1278
134. Holland SM. Nontuberculous mycobacteria. Am J Med Sci 2001;321:49-55.
135. Colin AA. Eradication of Mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000;30:267-268
136. Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J Respir Crit Care Med 2000;161(2 pt 1):641-645
137. Hayes D Jr. Mycobacterium abscessus and other nontuberculous mycobacteria: evolving respiratory pathogens in cystic fibrosis - a case report and review. South Med J 2005;98: 657-661
138. Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon gamma for Mycobacterium avium-complex lung disease. Am J Respir Crit Care Med 1995;152: 1094-1096
139. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997;349:1513-1515 (Pubitemid 27216363)
140. Koh WJ, Kwon OJ, Suh GY, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004;19:167-171 (Pubitemid 38591787)
141. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51(RR-8):1-52.
142. Centers for Disease Control and Prevention, Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10):1-125, CE1-7.
143. U.S. Food and Drug Administration. Information for healthcare professionals on colistimethate. Available from http://www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm124894.pdf. Accessed January 26, 2010.
144. U.S. Food and Drug Administration. GlaxoSmithKline, important drug warning: Relenza inhalation powder must not be nebulized. Available from http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/UCM186224pdf. Accessed October 15, 2009.
145. Melani AS, Di Gregorio A. Acute respiratory failure due to gentamicin aerosolization. Monaldi Arch Chest Dis 1998;53:274-276 (Pubitemid 28461654)
146. Nikolaizik WH, Jenni-Galovic V, Schoni MH. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Eur J Pediatr 1996;155:608-611 (Pubitemid 26231578)
147. Alothman GA, Alsaadi MM, Ho BL, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122:930-934
148. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002;20:122-126 (Pubitemid 34822933)
149. Ramagopal M, Lands LC. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr Pulmonol 2000;29: 366-370 (Pubitemid 30230424)
150. Dominguez-Ortega J, Manteiga E, Abad-Schilling C, Juretzcke MA, Sanchez-Rubio J, Kindelan C. Induced tolerance to nebulized colistin after severe reaction to the drug. J Investig Allergol Clin Immunol 2007;17:59-61. (Pubitemid 46280165)
151. Balmes JR, Estacio PL, Quinlan P, Kelly T, Corkery K, Blanc P. Respiratory effects of occupational exposure to aerosolized pentamidine. J Occup Environ Med 1995;37:145-150
152. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997;127:922-946
153. American College of Chest Physicians. Aerosol consensus statement. Consensus conference on aerosol delivery. Chest 1991;100:1106-1109
154. Dooley SW Jr, Castro KG, Hutton MD, Mullan RJ, Polder JA, Snider DE Jr. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR Recomm Rep
155. Centers for Disease Control. Mycobacterium tuberculosis transmission in a health clinic - Florida, 1988. MMWR Morb Mortal Wkly Rep 1989;38:256-8, 263-264
156. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR Recomm Rep 1994;43(RR-13):1-132.
157. Jakobsson BM, Onnered AB, Hjelte L, Nystrom B. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients. J Hosp Infect 1997;36:201-207 (Pubitemid 27354774)
158. Rosenfeld M, Emerson J, Astley S, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132:125-131
159. Bowman CM. The long-term use of inhaled tobramycin in patients with cystic fibrosis. J Cyst Fibros 2002;1(suppl 2):194-198
160. Cannella CA, Wilkinson ST. Acute renal failure associated with inhaled tobramycin. Am J Health Syst Pharm 2006;63: 1858-1861 (Pubitemid 44477457)
161. Laporta R, Ussetti P, Carreno MC. Renal toxicity due to inhaled tobramycin in lung transplant recipients [letter]. J Heart Lung Transplant 2006;25:608.
162. Izquierdo MJ, Gomez-Alamillo C, Ortiz F, et al. Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol 2006;66:464-467
163. Ahya VN, Doyle AM, Mendez JD, et al. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005;24:932-935
164. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375-377 (Pubitemid 35192792)
165. Edson RS, Brey RH, McDonald TJ, Terrell CL, McCarthy JT, Thibert JM. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004;79:1185-1191
166. Patatanian L. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Pediatr Infect Dis J 2006;25:276-278 (Pubitemid 43379077)
167. Badia JR, Soy D, Adrover M, et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004;54:508-514 (Pubitemid 39177478)
168. Kim CS, Eldrige MA, Sackner MA. Delivery efficiency of aerosols in intubated subjects [abstract]. Am Rev Respir Dis 1984;129:A110.
169. Ortho-McNeil Pharmaceutical, Inc. Doribax (doripenem) product information. Raritan, NJ; 2009.
170. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-1341
171. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 2004;3:23-28
172. Slobbe L, Boersma E, Rijnders BJ. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008;21: 855-859
173. Lowry CM, Marty FM, Vargas SO, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007;9:121-125
174. Knechtel SA, Klepser ME. Safety of aerosolized amphotericin B. Expert Opin Drug Saf 2007;6:523-532
175. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. J Pharm Pharmacol 2005;57:1289-1295
176. Conces DJ Jr, Kraft JL, Vix VA, Tarver RD. Apical Pneumocystis carinii pneumonia after inhaled pentamidine prophylaxis. AJR Am J Roentgenol 1989;152:1193-1194
177. Edelstein H, McCabe RE. Atypical presentations of Pneumocystis carinii pneumonia in patients receiving inhaled pentamidine prophylaxis. Chest 1990;98:1366-1369
178. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-313 (Pubitemid 46608898)
179. Neville NE. A comparison of efficacy between aerosolized liposomal amikacin and tobramycin in a chronic rat lung model of P. aeruginosa [abstract]. In: Program and abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2007:A-791.
180. Rogers TL, Hu J, Yu Z, Johnston KP, Williams RO III. A novel particle engineering technology: spray-freezing into liquid. Int J Pharm 2002;242:93-100.
181. Alvarez CA, Wiederhold NP, McConville JT, et al. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect 2007;55: 68-74.
182. Hoeben BJ, Burgess DS, McConville JT, et al. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006;50:1552-1554
183. Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL. Suitability of caspofungin for aerosol delivery: physico-chemical profiling and nebulizer choice. Chest 2005;128: 3711-3716 (Pubitemid 41698718)
184. Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J 2008;10:254-260
185. Bayer HealthCare Pharmaceuticals Inc. Study to evaluate the safety and efficacy of ciprofloxacin (inhaled) in patients with cystic fibrosis. Available from http://clinicaltrials.gov/ct2/show/NCT00645788. Accessed April 10, 2009.
186. Aradigm Corporation. ARD-3100 and 3150 (liposomal ciprofloxacin). Available from http://www.aradigm.com/products-3100.html. Accessed April 10, 2009.
187. Hickey AJ, Lu D, Ashley ED, Stout J. Inhaled azithromycin therapy. J Aerosol Med 2006;19:54-60.
188. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430-435 (Pubitemid 40542580)
189. Schuschnig U, Klopfer E, Luber M, et al. In vitro deposition study of a levofloxacin solution into a novel human nasal cast model by the Pari VIBRent [poster 4388]. Poster presentation at the European Respiratory Society annual congress, Munich, Germany, September 2-6, 2006.